Media stories about Global Blood Therapeutics (NASDAQ:GBT) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Global Blood Therapeutics earned a news sentiment score of 0.25 on Accern’s scale. Accern also gave news headlines about the company an impact score of 46.8843319006891 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

These are some of the news headlines that may have effected Accern Sentiment’s scoring:

A number of brokerages recently issued reports on GBT. Cowen reiterated a “buy” rating and issued a $83.00 price objective on shares of Global Blood Therapeutics in a report on Thursday, November 9th. Wedbush reiterated an “ourperform” rating and issued a $73.00 price objective on shares of Global Blood Therapeutics in a report on Monday, September 18th. Zacks Investment Research cut shares of Global Blood Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, November 7th. Oppenheimer set a $53.00 price objective on shares of Global Blood Therapeutics and gave the stock a “buy” rating in a report on Monday, November 13th. Finally, SunTrust Banks upped their price objective on shares of Global Blood Therapeutics to $67.00 and gave the stock a “buy” rating in a report on Monday, November 6th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and fourteen have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $56.38.

Shares of Global Blood Therapeutics (GBT) opened at $45.70 on Monday. Global Blood Therapeutics has a fifty-two week low of $13.35 and a fifty-two week high of $45.75.

Global Blood Therapeutics (NASDAQ:GBT) last released its quarterly earnings results on Thursday, November 2nd. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.62) by ($0.04). During the same quarter in the prior year, the company posted ($0.58) EPS. equities research analysts expect that Global Blood Therapeutics will post -2.55 earnings per share for the current year.

In related news, Director Charles J. Homcy sold 70,000 shares of the stock in a transaction dated Friday, October 27th. The shares were sold at an average price of $33.97, for a total value of $2,377,900.00. Following the completion of the sale, the director now owns 83,328 shares in the company, valued at $2,830,652.16. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Peter Radovich sold 12,500 shares of the stock in a transaction dated Monday, October 30th. The shares were sold at an average price of $35.00, for a total transaction of $437,500.00. Following the completion of the sale, the vice president now owns 2,684 shares of the company’s stock, valued at approximately $93,940. The disclosure for this sale can be found here. Insiders have sold 88,500 shares of company stock valued at $3,003,350 over the last 90 days. Corporate insiders own 5.30% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Global Blood Therapeutics (GBT) Earning Somewhat Positive Media Coverage, Report Finds” was first published by Watch List News and is owned by of Watch List News. If you are reading this report on another website, it was illegally copied and reposted in violation of United States and international trademark & copyright laws. The legal version of this report can be read at https://www.watchlistnews.com/global-blood-therapeutics-gbt-earning-somewhat-positive-media-coverage-report-finds/1756577.html.

Global Blood Therapeutics Company Profile

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

Insider Buying and Selling by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.